ClinicaliQ Trial Snapshot
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07613294.
- What is being tested: Lepodisiran, an investigational therapy designed to reduce lipoprotein(a) [Lp(a)] levels, is being evaluated for its ability to reduce coronary artery plaque burden in adults with elevated Lp(a) using imaging endpoints.
- Patient eligibility overview: Adults with elevated Lp(a) who have established cardiovascular disease (prior heart events) or are at high cardiovascular risk are eligible; this targets the population with the greatest clinical need.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a). Participation will last about 120 weeks.
Eligibility Snapshot
- : * Have an Lp(a) ≥175 nmol/L * Have established cardiovascular (CV) disease or are at risk for a first CV event * Have angiographic evidence of coronary artery disease on screening CCTA * If taking lipid-lowering medications, inclusive of statins or prescription strength niacin and PCSK9 inhibitors, these should be stable for 8 weeks
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.